Embecta (NASDAQ:EMBC) Issues FY 2025 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.700-2.900 for the period, compared to the consensus earnings per share estimate of 2.270. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analysts Forecast Growth

Separately, BTIG Research upgraded shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a report on Wednesday.

Embecta Trading Up 29.8 %

NASDAQ EMBC opened at $18.70 on Wednesday. The stock’s fifty day moving average price is $14.33 and its 200-day moving average price is $14.04. The stock has a market cap of $1.08 billion, a P/E ratio of 15.58 and a beta of 0.97. Embecta has a 12 month low of $9.93 and a 12 month high of $20.80.

Embecta Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Friday, December 6th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 3.21%. Embecta’s payout ratio is currently 50.00%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.